Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
Sell
-20,720
Closed -$1.04M 3157
2015
Q4
$1.04M Buy
20,720
+6,640
+47% +$338K 0.02% 814
2015
Q3
$677K Sell
14,080
-80
-0.6% -$4.16K 0.01% 1221
2015
Q2
$737K Buy
14,160
+2,000
+16% +$113K 0.01% 1136
2015
Q1
$701K Sell
12,160
-28,000
-70% -$1.61M 0.01% 1052
2014
Q4
$2.15M Buy
40,160
+12,000
+43% +$671K 0.04% 401
2014
Q3
$1.62M Sell
28,160
-12,400
-31% -$760K 0.03% 614
2014
Q2
$2.71M Sell
40,560
-34,560
-46% -$2.34M 0.04% 377
2014
Q1
$5.02M Sell
75,120
-6,560
-8% -$443K 0.06% 257
2013
Q4
$5.45M Buy
81,680
+44,080
+117% +$2.86M 0.06% 212
2013
Q3
$2.36M Buy
+37,600
New +$2.42M 0.03% 532

Other funds holding GSK

Virtu KCG Holdings's GSK Position: Q2 2017 in Review

Virtu KCG Holdings reduced its GSK (GSK) stake by 63% in Q2 2017, selling an estimated $1.55M and leaving 17,054 shares worth $919K. The position accounts for 0.03% of the portfolio, ranked #631.

Virtu KCG Holdings first reported a position in GSK in Q3 2013 and has held it in 15 quarters since. The position peaked at $17.7M in Q3 2013. 779 funds tracked by Wall St. Rank hold GSK as of Q2 2017.

  • Virtu KCG Holdings held 17,054 shares of GSK worth $919K as of Q2 2017.
  • Virtu KCG Holdings sold 29,060 GSK shares in Q2 2017, an estimated $1.55M.
  • GSK made up 0.03% of Virtu KCG Holdings's portfolio in Q2 2017, its #631 holding.
  • Virtu KCG Holdings first reported a position in GSK in Q3 2013 and has held it in 15 quarters since.
  • Virtu KCG Holdings's GSK position peaked at $17.7M in Q3 2013.
  • 779 funds tracked by Wall St. Rank held GSK as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.